Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 4/20 | 0.36 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.35 |
| ▸ | VNN1 | O95497 | 6/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18558081 | 0.94 | MAPK1 (0.37) | MAPK1GPR139VNN1GRM5 | |
| SCHEMBL18558452 | 0.91 | GPR139 (0.35) | MAPK1GPR139VNN1GRM5 | |
| SCHEMBL18558074 | 0.89 | CNR1 (0.40) | MAPK1GPR139VNN1GRM5 | |
| SCHEMBL18558338 | 0.88 | GPR139 (0.38) | MAPK1GPR139VNN1GRM5 | |
| SCHEMBL18558455 | 0.87 | VNN1 (0.35) | MAPK1VNN1GRM5 | |
| SCHEMBL18558028 | 0.87 | VNN1 (0.39) | MAPK1GPR139VNN1GRM5 | |
| SCHEMBL19362692 | 0.83 | GRM5 (0.41) | VNN1GRM5 | |
| SCHEMBL19362653 | 0.82 | VNN1 (0.38) | MAPK1GPR139VNN1 | |
| SCHEMBL18558360 | 0.82 | ADORA3 (0.38) | MAPK1GPR139 | |
| SCHEMBL18558512 | 0.82 | S1PR1 (0.40) | MAPK1GPR139VNN1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9932313-B2 | Pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2018-04-03 | — | — | US | disclosed |
| US-20170267643-A1 | PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2017-09-21 | — | — | US | disclosed |
| US-9580388-B2 | Pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267643-A1 | PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | ATP5F1A, ATP5F1D, ATP5ME | MAPK1 2483/4885GPR139 4205/4885VNN1 2342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.